Document Detail


Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments.
MedLine Citation:
PMID:  16583408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The TaqI A polymorphism (A(1)) of the dopamine D(2) receptor gene (DRD2), although not a specific predictor of opioid dependence, has been strongly associated with high levels of prior heroin use and poor treatment outcomes among methadone maintenance patients. The aims of this study were to confirm these findings via a retrospective analysis of A(1) allele frequency in methadone (n = 46) and buprenorphine (n = 25) patients, and non-opioid-dependent controls (n = 95). Subjects were genotyped at the DRD2 TaqI A locus using PCR amplification followed by TaqI restriction enzyme digestion and gel electrophoresis. For methadone and buprenorphine subjects, heroin use (prior to treatment), treatment outcomes, and withdrawal occurrence were determined from comprehensive case notes. No significant differences in A(1) allele frequency (%) were observed between: methadone (19.6%), buprenorphine (18.0%), and control (17.9%) groups (P > 0.7); successful and poor treatment outcome groups, methadone: 20.0% and 19.2%, respectively (P = 1.0); buprenorphine: 18.4% and 20.0%, respectively (P = 1.0). Also, there were no significant relationships between TaqI A genotype and prior heroin use (P = 0.47). However, among the successful methadone subjects, significantly fewer A(1) allele carriers experienced withdrawal than non-A(1) carriers (P = 0.04). In conclusion, the DRD2 genotype effects did not affect opioid maintenance treatment outcomes. This suggests the need for a further prospective investigation into the role of the DRD2 A(1) allele in heroin use and response to maintenance pharmacotherapies for opioid dependence.
Authors:
Daniel T Barratt; Janet K Coller; Andrew A Somogyi
Related Documents :
24845488 - Buprenorphine and methadone for opioid addiction during pregnancy.
25422798 - Management of hyperthyroidism in pregnancy: results of a survey among members of the eu...
21242588 - Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated bre...
12475578 - Antigenic and functional levels of alpha-1-antitrypsin in serum during normal and diabe...
21264878 - Hematological effects of zidovudine prophylaxis in newborn infants with and without pre...
10367418 - Prenatal screening for chromosome abnormalities.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics     Volume:  141B     ISSN:  1552-4841     ISO Abbreviation:  Am. J. Med. Genet. B Neuropsychiatr. Genet.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-25     Completed Date:  2006-08-16     Revised Date:  2008-08-29    
Medline Journal Info:
Nlm Unique ID:  101235742     Medline TA:  Am J Med Genet B Neuropsychiatr Genet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  323-31     Citation Subset:  IM    
Affiliation:
Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia. daniel.barratt@adelaide.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alleles
Analgesics, Opioid / therapeutic use
Buprenorphine / therapeutic use*
Deoxyribonucleases, Type II Site-Specific / metabolism
Female
Gene Frequency
Genotype
Heroin Dependence / genetics*,  physiopathology,  rehabilitation
Humans
Male
Methadone / therapeutic use*
Receptors, Dopamine D2 / genetics*,  metabolism
Retrospective Studies
Substance Withdrawal Syndrome / physiopathology
Time Factors
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 DA13706-02/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 0/Receptors, Dopamine D2; 52485-79-7/Buprenorphine; 76-99-3/Methadone; EC 3.1.21.4/Deoxyribonucleases, Type II Site-Specific; EC 3.1.21.4/TCGA-specific type II deoxyribonucleases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preliminary evidence for an association between a dopamine D3 receptor gene variant and obsessive-co...
Next Document:  Illness intrusion and psychological adjustment to rheumatic diseases: a social identity framework.